<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603653</url>
  </required_header>
  <id_info>
    <org_study_id>C15-02</org_study_id>
    <secondary_id>IDRCB</secondary_id>
    <nct_id>NCT02603653</nct_id>
  </id_info>
  <brief_title>Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease</brief_title>
  <acronym>MEMOCUSH</acronym>
  <official_title>Cognitive Sequels of Cushing Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cushing's disease is a state of chronic endogenous glucocorticoid excess. Cushing's disease&#xD;
      is responsible for increased morbidity and mortality. Recent studies have pinpointed the&#xD;
      frequency of somatic sequelas and persistent alteration in quality of life despite the cure&#xD;
      of the disease. More specifically, a few studies have described persistent psychopathology,&#xD;
      maladaptive personality and cognitive impairments in patients with a history of Cushing's&#xD;
      disease. Among these, hippocampal memory deficits have been found in the majority of studies,&#xD;
      a finding that is consistent with the alterations described in hippocampal neurons during&#xD;
      chronic exposure to glucocorticoids. However, the tools currently available to assess&#xD;
      hippocampal-dependent memory are multiple, sometimes difficult to perform by clinicians and&#xD;
      to analyze or may lack of diagnostic sensitivity. The investigators have recently developed&#xD;
      an original tool, the virtual radial task in 3D, which has shown to be reliable to detect&#xD;
      subtle alterations in hippocampal-dependent memory in several human diseases. The primary aim&#xD;
      of the study is the evaluation of persistent cognitive impairments (hippocampal memory) in&#xD;
      patients cured of Cushing's disease for at least one year using the virtual radial task in 3D&#xD;
      and to compare it with that obtained with classical cognitive tests.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of right answers at virtual radial task in 3D</measure>
    <time_frame>baseline</time_frame>
    <description>Comparison of right answers in patients cured of Cushing's disease and in controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>General Quality of life</measure>
    <time_frame>baseline</time_frame>
    <description>Comparison of quality of life of patients and controls with validated general questionnaire : SF-36 (SF for Short Form health survey)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Quality of life for Cushing's Disease</measure>
    <time_frame>baseline</time_frame>
    <description>Comparison of quality of life of patients and controls with validated specific questionnaire for Cushing's Disease : Cushing-QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anxiety</measure>
    <time_frame>baseline</time_frame>
    <description>Evaluation of anxiety in the two groups with Hospital Anxiety and Depression Scale (HADS) scale (questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with depression with MADRS</measure>
    <time_frame>baseline</time_frame>
    <description>Evaluation of depression in the two groups with Montgomery and Asberg Depression Rating Scale (MADRS) (questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with depression with HADS</measure>
    <time_frame>baseline</time_frame>
    <description>Evaluation of depression in the two groups with Hospital Anxiety and Depression Scale (HADS) scale (questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Cushing's syndrome</measure>
    <time_frame>baseline</time_frame>
    <description>Intensity of Cushing's disease will be evaluated with mean of free urinary cortisol. Hypothesis : intensity of hypercortisolism is correlated with sequels after cure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cushing's Disease</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Virtual radial task in 3D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Virtual radial task in 3D</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Virtual radial task in 3D</intervention_name>
    <description>The virtual radial task is a labyrinth in 3D with twelve ways. The primary aim of our study is the evaluation of persistent cognitive impairments (hippocampal memory) according to the responses of participants after instructions to choose the right way in the labyrinth.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients :&#xD;
&#xD;
          -  history of Cushing's Disease&#xD;
&#xD;
          -  aged : 18 - 60 years&#xD;
&#xD;
          -  Biological remission of Cushing's disease for at least one year&#xD;
&#xD;
          -  Affiliation to Social Security&#xD;
&#xD;
          -  Informed consent signed by patient and investigator (at the latest the inclusion's&#xD;
             day, before study's exams)&#xD;
&#xD;
        For controls :&#xD;
&#xD;
          -  People aged 18 to 60 years matched to patients for age, sex and educational level&#xD;
&#xD;
          -  Affiliation to Social Security&#xD;
&#xD;
          -  Informed consent signed by patient and investigator (at the latest the inclusion's&#xD;
             day, before study's exams)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For patients :&#xD;
&#xD;
          -  Persistent hypercortisolism (even mild)&#xD;
&#xD;
          -  Current treatment of hypercortisolism with drugs&#xD;
&#xD;
          -  Obesity (BMI &gt;30 kg/m²)&#xD;
&#xD;
          -  Alcohol or drug addiction present or past&#xD;
&#xD;
          -  Growth hormone deficit&#xD;
&#xD;
          -  Diabetes mellitus with hemoglobin A1c &gt; 7.5% and/or fasting blood glucose &gt; 1.4 g/L&#xD;
&#xD;
          -  History of pituitary radiotherapy&#xD;
&#xD;
          -  History of cerebrovascular or neuro-cerebral disease&#xD;
&#xD;
          -  untreated dysthyroidism&#xD;
&#xD;
          -  Current psychotropic drug treatment&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Use of glucocorticoids in the last 3 months before study (aside hydrocortisone&#xD;
             replacement therapy)&#xD;
&#xD;
          -  Excessive hydrocortisone replacement therapy (unadjusted to weight and/or with evening&#xD;
             administration)&#xD;
&#xD;
        For controls :&#xD;
&#xD;
          -  Obesity (BMI &gt;30 kg/m²)&#xD;
&#xD;
          -  Alcohol or drug addiction present or past&#xD;
&#xD;
          -  Current psychotropic drug treatment&#xD;
&#xD;
          -  History of cerebrovascular or neuro-cerebral disease&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  Chronical use of corticoid (&gt; 1 month), current or past&#xD;
&#xD;
          -  Use of glucocorticoids in the last 3 months before study (aside hydrocortisone&#xD;
             replacement therapy)&#xD;
&#xD;
          -  Diabetes mellitus with hemoglobin A1c &gt; 7.5% and/or fasting blood glucose &gt; 1.4 g/L&#xD;
&#xD;
          -  Obesity (BMI &gt;30 kg/m²)&#xD;
&#xD;
          -  untreated dysthyroidism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Tabarin, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Haut Lévêque - Pessac (France)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine Tabarin, Pr</last_name>
    <email>antoine.tabarin@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital du Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Antoine Tabarin, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>November 10, 2015</last_update_submitted>
  <last_update_submitted_qc>November 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
    <mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

